

```

s prostate
  S1      2048  PROSTATE
? s immunoconjugate
  S2      93    IMMUNOCONJUGATE
? s s1 and s2
      2048  S1
      93    S2
  S3      6    S1 AND S2
? rd
>>>Duplicate detection is not supported for File 340.
>>>All specified files are unsupported, command ignored.
? t s3/3,k,ab/1-6

```

3/3,K,AB/1  
DIALOG(R)File 340:CLAIMS(R)/US Patent  
(c) 2002 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10159024 IFI Acc No: 2002-0102666 IFI Acc No: 2002-0026309  
Document Type: C  
PSCA: **PROSTATE** STEM CELL ANTIGEN AND USES THEREOF  
Inventors: Jakobovits Aya (US); Reiter Robert E (US); Saffran Douglas C (US); Witte Owen N (US)  
Assignee: California, University of Regents  
Assignee Code: 13234  
Publication (No,Date), Applic (No,Date):  
US 20020102666 20020801 US 2001855153 20010514  
Publication Kind: A1  
Cont.-in-part Pub(No),Applic(No,Date): GRANTED US 9838261  
19980310; GRANTED US 98203939 19981202; GRANTED  
US 99251835 19990217; GRANTED US 99318503  
19990525; PENDING US 99359326 19990720  
Division Pub(No),Applic(No,Date): PENDING US 2000564329  
20000503  
Priority Applic(No,Date): US 2001855153 20010514; US 9838261 19980310;  
US 98203939 19981202; US 99251835 19990217; US 99318503 19990525;  
US 99359326 19990720; US 2000564329 20000503  
Provisional Applic(No,Date): US 60-71141 19980112; US 60-74675  
19980213; US 60-113230 19981221; US 60-120536 19990217; US 60-124658  
19990316; US 60-228816 19970310

Abstract: The invention provides a novel **prostate** cell-surface antigen, designated **Prostate** Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of **prostate** cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgendependent and androgen-independent **prostate** tumors.

PSCA: **PROSTATE** STEM CELL ANTIGEN AND USES THEREOF

Abstract: The invention provides a novel **prostate** cell-surface antigen, designated **Prostate** Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of **prostate** cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgendependent and androgen-independent **prostate** tumors.

Non-exemplary Claims: ...17. An **immunoconjugate** comprising the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 8 joined...

...18. An **immunoconjugate** comprising the recombinant protein of claim 11 joined to a therapeutic agent...

...19. An **immunoconjugate** comprising the polypeptide of claim 12 joined to a therapeutic agent...

...20. An **immunoconjugate** comprising the monoclonal antibody of claim 9 joined to a therapeutic agent...

- ...21. An **immunoconjugate** comprising the bispecific antibody of claim 14 joined to a therapeutic agent...
- ...22. An **immunoconjugate** comprising the single chain antibody molecule of claim 16 joined to a therapeutic agent...
- ...23. The **immunoconjugate** of any one of claims 17-22, wherein the therapeutic agent is a cytotoxic agent...
- ...24. The **immunoconjugate** of claim 23, wherein the cytotoxic agent is selected from a group consisting of ricin...
- ...expressing the PSCA antigen on the cell surface, comprising a pharmaceutically effective amount of the **immunoconjugate** of any one of the claims 17-22, and a pharmaceutically acceptable carrier...
- ...on the cell surface which comprises administering to the subject an effective amount of an **immunoconjugate** of any one of the claims 17-22 such that the **immunoconjugate** binds the PSCA antigen and kills said cells thereby treating the subject...38. The method of claim 29, wherein the cancer is **prostate** cancer...
- ...39. The method of claim 29, wherein the cancer is metastatic **prostate** cancer...

3/3,K,AB/2

DIALOG(R) File 340:CLAIMS(R)/US Patent

(c) 2002 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10154875 IFI Acc No: 2002-0098516 IFI Acc No: 2002-0025158

Document Type: C

IMMUNODIAGNOSTIC DETERMINATION OF USHER SYNDROME TYPE IIA

Inventors: Cosgrove Dominic E (US)

Assignee: BOYSTOWN NATIONAL Res HOSPITAL

Publication (No,Date), Applic (No,Date):

US 20020098516 20020725 US 2001970318 20011003

Publication Kind: A1

Priority Applic(No,Date): US 2001970318 20011003

Provisional Applic(No,Date): US 60-237834 20001003

Abstract: Methods and test kits for determining whether an individual has or is at risk for developing Usher syndrome Type IIa. The methods include obtaining a biological sample from an individual, incubating the biological sample with at least one antibody which is immunoreactive with an USH2a protein under conditions effective to produce immunoconjugates if the usherin protein is present, evaluating for the presence or absence of immunoconjugates, and correlating the presence of immunoconjugates with the individual not having Usher syndrome Type IIa, and the absence of immunoconjugates with the individual having or being at risk for developing Usher syndrome Type IIa.

Exemplary Claim: ...at least a portion of a human usherin protein under conditions effective to produce an **immunoconjugate** if the usherin protein is present, wherein a complement of a polynucleotide encoding the usherin...

...NO:3 under highly stringent hybridization conditions; evaluating for the presence or absence of the **immunoconjugate**; and correlating the presence of the **immunoconjugate** with the individual not having Usher syndrome Type IIa, and the absence of the **immunoconjugate** with the individual having or being at risk for developing Usher syndrome Type IIa.

Non-exemplary Claims: ...group consisting of at least a portion of testis, cochlea, epididymus, ovary, eye, uterus, heart, pancreas, **prostate**, skin, placenta, spleen, submaxillary gland, small intestine, large intestine, blood vessels, and combinations thereof...

...at least a portion of a human usherin protein under conditions effective to produce an **immunoconjugate** if the usherin protein is present, wherein a complement of a polynucleotide encoding the usherin...

...NO:3 under highly stringent hybridization conditions; evaluating for the presence or absence of the **immunoconjugate**; correlating the presence of the **immunoconjugate** with the presence of usherin protein, and the absence of the **immunoconjugate** with the absence of the usherin protein...

...consisting of at least a portion of testis, cochlea, epididymus, ovary, eye, uterus, heart, pancreas, **prostate**, skin, placenta, spleen, submaxillary gland, small intestine, large intestine, blood vessels, and combinations thereof...at least a portion of a human usherin protein under conditions effective to produce an **immunoconjugate** if the usherin protein is present, wherein a complement of a polynucleotide encoding the usherin...

...NO:3 under highly stringent hybridization conditions; evaluating for the presence or absence of the **immunoconjugate**; and correlating the presence of the **immunoconjugate** with the individual not having Usher syndrome Type IIa, and the absence of the **immunoconjugate** with the individual having or being at risk for developing Usher syndrome Type IIa...

...16. The method of claim 15 wherein the **immunoconjugate** is a sandwich comprising the first antibody, the second antibody, and the human usherin protein...with at least a portion of human usherin protein under conditions effective to produce an **immunoconjugate** if the usherin protein is present, wherein the absence of an **immunoconjugate** correlates to the diagnosis of or the individual being at risk for developing Usher Type...

3/3,K,AB/3  
 DIALOG(R) File 340:CLAIMS(R)/US Patent  
 (c) 2002 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10065922 IFI Acc No: 2002-0009455 IFI Acc No: 2002-0002418  
 Document Type: C  
 DNA ENCODING A NOVEL PROST 03 POLYPEPTIDE  
 Inventors: Heuit Pamela Toy Van (US); Lau Ted (US); Lin Richard J (US);  
 Parkes Deborah (US); Parry Gordon (US); Schneider Douglas W (US);  
 Steinbrecher Renate (US); Wu John (US)  
 Assignee: Unassigned Or Assigned To Individual  
 Assignee Code: 68000  
 Publication (No,Date), Applic (No,Date):  
 US 20020009455 20020124 US 2001838785 20010420  
 Publication Kind: A1  
 Priority Applic(No,Date): US 2001838785 20010420  
 Provisional Applic(No,Date): US 60-200065 20000427

Abstract: The present invention relates to novel human polypeptides, designated PROST 03, which exhibit an expression pattern showing a high specificity toward **prostate** tissues, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.

Abstract: ...human polypeptides, designated PROST 03, which exhibit an expression pattern showing a high specificity toward **prostate** tissues, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered...

Non-exemplary Claims: ...24. An **immunoconjugate** comprising an isolated antibody, or antibody fragment, which specifically binds to a polypeptide comprising a...

...25. The **immunoconjugate** of claim 24, wherein the therapeutic agent is a cytotoxic agent 26. The **immunoconjugate** of claim 25, wherein the cytotoxic agent is selected from the group consisting of ricin...

...27. The **immunoconjugate** of claim 24, wherein the antibody fragments are selected from the group consisting of Fv...

...a cell expressing the polypeptide of FIG. 2 (SEQ ID NO: 2) comprising reacting the **immunoconjugate** of claim 24 with the cell so that the therapeutic agent of the **immunoconjugate** can destroy the cell...

...and wherein the method comprises administering to the patient a therapeutically effective amount of the **immunoconjugate** of claim 24...nontoxic vehicle, which amount is effective to induce an immune response in a human against **prostate** cancer associated with PROST 03 expression...

...amount of said polypeptide or fragment, which amount is effective to immunize a human against **prostate** cancer associated with PROST 03 expression.

3/3,K,AB/4

DIALOG(R) File 340:CLAIMS(R)/US Patent

(c) 2002 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10058088 IFI Acc No: 2002-0001588 IFI Acc No: 2002-0000193

Document Type: C

TARGETING OF ORGANS BY IMMUNOCONJUGATES

Inventors: Sinha Akhouri A (US)

Assignee: Unassigned Or Assigned To Individual

Assignee Code: 68000

Publication (No,Date), Applic (No,Date):

US 20020001588 20020103 US 2001930508 20010815

Publication Kind: A1

Division Pub(No), Applic(No,Date):

US 96691565

19960802

Priority Applic(No,Date): US 2001930508 20010815; US 96691565 19960802

Provisional Applic(No,Date): US 60-1892 19950804

Abstract: Bioactive materials, e.g. therapeutic agents for treating a condition that afflicts a patient, are delivered to the afflicted organ in a site-specific manner by coupling the bioactive agent to an antibody or fragment or derivative thereof that recognizes a substance unique to that organ. For example, therapeutic agents for treating conditions of the **prostate** gland such as adenocarcinoma of the **prostate**, benign prostatic hypertrophy and prostatitis can be delivered to the **prostate** by coupling the therapeutic agent to an antibody against a substance secreted by the **prostate**, e.g. prostatic specific antigen or prostatic acid phosphatase.

Abstract: ...a substance unique to that organ. For example, therapeutic agents for treating conditions of the **prostate** gland such as adenocarcinoma of the **prostate**, benign prostatic hypertrophy and

prostatitis can be delivered to the **prostate** by coupling the therapeutic agent to an antibody against a substance secreted by the **prostate**, e.g. prostatic specific antigen or prostatic acid phosphatase.

Exemplary Claim: 1. An **immunoconjugate** that recognizes a substance unique to an organ, comprising an antibody or derivative or fragment...

Non-exemplary Claims: 2. The conjugate of claim 1 wherein the organ is a **prostate** gland...

...3. The conjugate of claim 2 wherein the **prostate** is cancerous...

...4. The conjugate of claim 2 wherein the **prostate** is a human **prostate**.  
...

...5. The **immunoconjugate** of claim 1 wherein the antibody is an IgG  
...

...a bioactive substance to an organ in an animal, comprising administering to the animal an **immunoconjugate** which comprises an antibody or derivative or fragment thereof for a substance which is unique...

...14. The method of claim 10, wherein the organ is the **prostate**.  
...

...15. The method of claim 14, wherein the **prostate** is afflicted with adenocarcinoma of the **prostate**, benign prostatic hypertrophy or prostatitis.

3/3,K,AB/5

DIALOG(R) File 340:CLAIMS(R)/US Patent  
(c) 2002 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10055592 IFI Acc No: 2001-0055751 IFI Acc No: 2001-0014174  
Document Type: C

PSCA: **PROSTATE** STEM CELL ANTIGEN AND USES THEREOF

Inventors: Jakobovits Aya (US); Reiter Robert E (US); Saffran Douglas C (US); Witte Owen N (US)

Assignee: Unassigned Or Assigned To Individual

Assignee Code: 68000

Publication (No,Date), Applic (No,Date):

US 20010055751 20011227 US 2000564329 20000503

Publication Kind: A1

Cont.-in-part Pub(No),Applic(No,Date): US 6267960 US 9838261

19980310; US 6258939 US 9820393 19981202; US 6261789

US 99251835 19990217; US 6261791 US 99318503

19990525; US 99359326 19990720

Priority Applic(No,Date): US 2000564329 20000503; US 9838261 19980310;

US 9820393 19981202; US 99251835 19990217; US 99318503 19990525;

US 99359326 19990720

Provisional Applic(No,Date): US 60-71141 19980112; US 60-74675

19980213; US 60-113230 19981221; US 60-120536 19990217; US 60-124658

19990316; US 60-228816 19970310

Abstract: The invention provides a novel **prostate** cell-surface antigen, designated **Prostate** Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of **prostate** cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent **prostate** tumors.

PSCA: **PROSTATE** STEM CELL ANTIGEN AND USES THEREOF

Abstract: The invention provides a novel **prostate** cell-surface antigen, designated **Prostate Stem Cell Antigen (PSCA)**, which is widely over-expressed across all stages of **prostate** cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent **prostate** tumors.

Non-exemplary Claims: ...17. An **immunoconjugate** comprising the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 8 joined...

...18. An **immunoconjugate** comprising the recombinant protein of claim 11 joined to a therapeutic agent...

...19. An **immunoconjugate** comprising the polypeptide of claim 12 joined to a therapeutic agent...

...20. An **immunoconjugate** comprising the monoclonal antibody of claim 9 joined to a therapeutic agent...

...21. An **immunoconjugate** comprising the bispecific antibody of claim 14 joined to a therapeutic agent...

...22. An **immunoconjugate** comprising the single chain antibody molecule of claim 16 joined to a therapeutic agent...

...23. The **immunoconjugate** of any one of claims 17-22, wherein the therapeutic agent is a cytotoxic agent...

...24. The **immunoconjugate** of claim 23, wherein the cytotoxic agent is selected from a group consisting of ricin...

...expressing the PSCA antigen on the cell surface, comprising a pharmaceutically effective amount of the **immunoconjugate** of any one of the claims 17-22, and a pharmaceutically acceptable carrier...

...on the cell surface which comprises administering to the subject an effective amount of an **immunoconjugate** of any one of the claims 17-22 such that the **immunoconjugate** binds the PSCA antigen and kills said cells thereby treating the subject...38. The method of claim 29, wherein the cancer is **prostate** cancer...

...39. The method of claim 29, wherein the cancer is metastatic **prostate** cancer...

3/3,K,AB/6

DIALOG(R) File 340:CLAIMS(R)/US Patent

(c) 2002 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 3673854 IFI Acc No: 0212594

Document Type: C

TARGETING OF ORGANS BY IMMUNOCONJUGATES

Inventors: Sinha Akhouri A (US)

Assignee: Unassigned Or Assigned To Individual

Assignee Code: 68000

Publication (No,Date), Applic (No,Date):

US 6379669 20020430 US 96691565 19960802

Calculated Expiration: 20160802

Priority Applic(No,Date): US 96691565 19960802

Abstract: Bioactive materials, e.g. therapeutic agents for treating a condition that afflicts a patient, are delivered to the afflicted organ in a site-specific manner by coupling the bioactive agent to an antibody or fragment or derivative thereof that recognizes a substance unique to that organ. For example, therapeutic agents for treating conditions of the **prostate** gland such as adenocarcinoma of the **prostate**, benign prostatic hypertrophy and prostatitis can be delivered to the

**prostate** by coupling the thereapeutic agent to an antibody against a substance secreted by the **prostate**, e.g. prostatic specific antigen or prostatic acid phosphatase.

Abstract: ...a substance unique to that organ. For example, therapeutic agents for treating conditions of the **prostate** gland such as adenocarcinoma of the **prostate**, benign prostatic hypertrophy and prostatitis can be delivered to the **prostate** by coupling the thereapeutic agent to an antibody against a substance secreted by the **prostate**, e.g. prostatic specific antigen or prostatic acid phosphatase.

Exemplary Claim: ...A W I N G

1. A method for delivering a bioactive substance to a **prostate** gland in an animal, comprising administering to the animal an **immunoconjugate** which comprises an antibody or antigen-binding fragment thereof for **prostate** specific antigen linked to a bioactive agent for treating a condition of the prostate gland.

Non-exemplary Claims: 2. The method of claim 1, wherein the **immunoconjugate** is administered by injection or delivered directly to the **prostate** gland...

...claim 1, wherein said condition is selected from the group consisting of adenocarcinoma of the **prostate**, benign prostatic hypertrophy and prostatitis...

?